Your browser doesn't support javascript.
loading
Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China.
Zhang, Chichen; Tu, Xiang; Dai, Jindong; Zhang, Zilong; Shen, Chenlan; Wu, Qiyou; Liu, Zhenhua; Lin, Tianhai; Qiu, Shi; Yang, Lu; Yang, Ling; Zhang, Mengni; Cai, Diming; Bao, Yige; Zeng, Hao; Wei, Qiang.
Afiliação
  • Zhang C; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Tu X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Dai J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhang Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Shen C; Department of Laboratory Medicine, Med+X Center for Manufacturing, West China Hospital, Sichuan University, Chengdu, China.
  • Wu Q; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Liu Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Lin T; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Qiu S; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Yang L; Department of Molecular Oncology, Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Yang L; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhang M; Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
  • Cai D; Department of Pathology and Laboratory of Pathology, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
  • Bao Y; Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, China.
  • Zeng H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Wei Q; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Prostate ; 84(6): 539-548, 2024 May.
Article em En | MEDLINE | ID: mdl-38173301
ABSTRACT

BACKGROUND:

Data on the utilization and effects of prebiopsy prostate multiparametric magnetic resonance imaging (mpMRI) to support its routine use in real-world setting are still scarce.

OBJECTIVE:

To evaluate the change of clinical practice of prebiopsy mpMRI over time, and assess its diagnostic accuracy. DESIGN, SETTING, AND

PARTICIPANTS:

We retrospectively analyzed data from 6168 patients who underwent primary prostate biopsy (PBx) between January 2011 and December 2021 and had prostate-specific antigen (PSA) values ranging from 3 to 100 ng/mL. INTERVENTION Prebiopsy MRI at the time of PBx. OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

We performed general linear regression and to elucidate trends in the annual use of prebiopsy mpMRI and conducted multivariable logistic regression to evaluate the potential benefits of incorporating prebiopsy mpMRI for prostate cancer (PCa) detection. RESULTS AND

LIMITATIONS:

The utilization of prebiopsy mpMRI significantly increased from 9.2% in 2011 to 75.0% in 2021 (p < 0.001). In addition, prebiopsy mpMRI significantly reduced negative PBx by 8.6% while improving the detection of clinically significant PCa (csPCa) by 7.0%. Regression analysis showed that the utilization of prebiopsy mpMRI was significantly associated with a 48% (95% confidence interval [CI] 1.19-1.84) and 36% (95% CI 1.12-1.66) increased PCa detection rate in the PSA 3-10 ng/mL and 10-20 ng/mL groups, respectively; and a 34% increased csPCa detection rate in the PSA 10-20 ng/mL group (95% CI 1.09-1.64). The retrospective design and the single center cohort constituted the limitations of this study.

CONCLUSIONS:

Our study demonstrated a notable rise in the utilization of prebiopsy mpMRI in the past decade. The adoption of this imaging technique was significantly associated with an increased probability of detecting prostate cancer. PATIENT

SUMMARY:

From 2011 to 2021, we demonstrated a steady increase in the utilization of prebiopsy mpMRI among biopsy-naïve men. We also confirmed the positive impact of prebiopsy mpMRI utilization on the detection of prostate cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article